Top

Published in:

01-05-2014 | Research Article

CXCR4 as a novel predictive biomarker for metastasis and poor prognosis in colorectal cancer

Authors: Ying Gao, Chunyu Li, Min Nie, Yao Lu, Shunsen Lin, Peng Yuan, Xun Sun

Published in: Tumor Biology | Issue 5/2014

Abstract

The clinical significance of CXCR4 expression in colorectal cancer remains unclear. The aim of this study was to investigate the expression and regulatory effects of CXCR4 in colorectal cancer and the association between CXCR4 protein expression and prognosis. The mRNA and protein expression levels of CXCR4 were determined using reverse-transcriptase polymerase chain reaction and immunohistochemistry staining, respectively, and the relationship between the CXCR4 protein level and clinicopathological parameters was analyzed in 720 cases of colorectal cancer. CXCR4 expression was elevated in colorectal cancer tissues compared to pericancerous tissues (P = 0.001). Of the 720 enrolled cases, 208 (28.89 %) expressed CXCR4. In univariate analysis, CXCR4 was found to be associated with lymph node metastasis, TNM stage, and liver metastasis (P = 0.001, 0.001, and 0.012, respectively). Further multivariate analysis suggested that histological grade, TNM stage, and CXCR4 expression were related to liver metastasis (P = 0.020, 0.01, and 0.001, respectively). In the Cox regression test, the histological grade, lymph node metastasis, TNM stage, liver metastasis, and CXCR4 expression were found to be independent prognostic factors (P = 0.02, 0.045, 0.01, 0.001, and 0.001, respectively). CXCR4 protein may be a potential biomarker for liver metastasis and an independent marker for survival in colorectal cancer.

Broadbridge VT, Karapetis CS, Beeke C, Woodman RJ, Padbury R, Maddern G, et al. Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival? Br J Cancer. 2013;109(5):1338–43.CrossRefPubMedPubMedCentral

Reames BN, Krell RW, Ponto SN, Wong SL. Critical evaluation of oncology clinical practice guidelines. J Clin Oncol. 2013;31(20):2563–8.CrossRefPubMedPubMedCentral

Deo SV, Kapali AS, Gupta M, Shukla NK. A review of controversies in the management of colorectal cancers. Indian J Surg. 2012;74(3):221–7.CrossRefPubMedPubMedCentral

Hyder O, Dodson RM, Mayo SC, Schneider EB, Weiss MJ, Herman JM, et al. Post-treatment surveillance of patients with colorectal cancer with surgically treated liver metastases. Surgery. 2013;154(2):256–65.CrossRefPubMedPubMedCentral

Eichler K, Dufas T, Hammerstingl R, Gruber-Rouh T, Vogl TJ, Zangos S. Hepatic arterial infusion with irinotecan in patients with liver metastases of colorectal cancer: results of an extended phase I study. Chemotherapy. 2013;59(1):66–73.CrossRefPubMed

Bullock MD, Bruce A, Sreekumar R, Curtis N, Cheung T, Reading I, et al. FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role. Br J Cancer. 2013;109(2):387–94.CrossRefPubMedPubMedCentral

Moriuchi M, Moriuchi H, Turner W, Fauci AS. Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. J Immunol. 1997;159(9):4322–9.PubMed

Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, Virelizier JL, et al. Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett. 1998;426(2):271–8.CrossRefPubMed

He H, Wang C, Shen Z, Fang Y, Wang X, Chen W, et al. Upregulated expression of C-x-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer. PLoS One. 2013;8(8):e71864.CrossRefPubMedPubMedCentral

10.

Qu QX, Huang Q, Xu J, Duan LT, Zhu YB, Zhang XG. CD40 signal regulates CXCR4 mediating ovarian carcinoma cell migration: implications for extrapelvic metastastic factors. Oncol Res. 2013;20(9):383–92.CrossRefPubMed

11.

Kremer KN, Peterson KL, Schneider PA, Meng XW, Dai H, Hess AD, et al. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. J Biol Chem. 2013;288(32):22899–914.CrossRefPubMedPubMedCentral

12.

Zhang HW, Sun XF, He YN, Li JT, Guo XH, Liu H. Bioinformatics analysis of breast cancer bone metastasis related gene-CXCR4. Asian Pac J Trop Med. 2013;6(9):732–8.CrossRefPubMed

13.

Gillies K, Wertman J, Charette N, Dupré DJ. Anterograde trafficking of CXCR4 and CCR2 receptors in a prostate cancer cell line. Cell Physiol Biochem. 2013;32(1):74–85.CrossRefPubMed

14.

Strong VE, D'Amico TA, Kleinberg L, Ajani J. Impact of the 7th edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw. 2013;11(1):60–6.CrossRefPubMed

15.

Abou-Bakr AA, Elbasmi A. c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. Gulf J Oncolog. 2013;1(14):28–34.PubMed

16.

Luo DH, Chen QY, Liu H, Xu LH, Zhang HZ, Zhang L, et al. The independent, unfavorable prognostic factors endothelin A receptor and chemokine receptor 4 have a close relationship in promoting the motility of nasopharyngeal carcinoma cells via the activation of AKT and MAPK pathways. J Transl Med. 2013;11(1):203.CrossRefPubMedPubMedCentral

17.

Segawa Y, Oda Y, Yamamoto H, Shiratsuchi H, Hirakawa N, Komune S, et al. Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma. Oncol Rep. 2009;21(5):1197–202.PubMed

Title: CXCR4 as a novel predictive biomarker for metastasis and poor prognosis in colorectal cancer
Authors: Ying Gao
Chunyu Li
Min Nie
Yao Lu
Shunsen Lin
Peng Yuan
Xun Sun
Publication date: 01-05-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1545-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

The association between the APE1 Asp148Glu polymorphism and breast cancer susceptibility: a meta-analysis based on case–control studies

The CYP1B1 Leu432Val polymorphism and risk of urinary system cancers

Expression profile of apoptosis-related genes potentially explains early recurrence after definitive chemoradiation in esophageal squamous cell carcinoma

Gene set enrichment analysis of the NF-κB/Snail/YY1/RKIP circuitry in multiple myeloma

Efficacy of Cisplatin-loaded polybutyl cyanoacrylate nanoparticles on the glioblastoma

DNA repair gene ERCC1 polymorphisms may contribute to the risk of glioma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer